The neurology landscape advanced across regulatory, clinical, and funding milestones today, with progress spanning Alzheimer’s, Parkinson’s disease, epilepsy, ADHD, frontotemporal dementia, and treatment-resistant depression. From China’s regulatory actions and FDA IND acceptances to Phase 2 trial preparations, regenerative medicine grants, and biomarker-driven collaborations, the day’s updates reflect a sector increasingly focused on execution, pairing established biology with improved delivery, precision diagnostics, and disciplined capital deployment to move CNS therapies closer to patients.
Cyclerion Expands Medsteer Partnership to Advance Closed-Loop Therapy for Treatment-Resistant Depression
Pulse:
- Cyclerion Therapeutics entered an expanded strategic collaboration with Medsteer to support the development of CYC-126, an anesthetic-based investigational therapy for treatment-resistant depression.
- The program integrates well-characterized anesthetic agents with real-time EEG monitoring and algorithm-guided dosing, aiming to guide patients toward specific brain states associated with antidepressant effects.
- Medsteer’s closed-loop delivery technology is expected to reduce execution risk while enabling individualized therapy, an approach that departs from conventional fixed-dose psychiatric treatments.
- Cyclerion plans to initiate a Phase 2 proof-of-concept study in 2026, positioning CYC-126 as a potential first-in-class precision neuropsychiatric therapy.
SynuSight, ABLi, and XingImaging Integrate Alpha-Synuclein PET Imaging Into Parkinson’s Trials
Pulse:
- SynuSight Biotech, ABLi Therapeutics, and XingImaging announced a collaboration to incorporate alpha-synuclein PET imaging into clinical trials evaluating risvodetinib for Parkinson’s disease.
- The partnership centers on F-FD4, a PET tracer designed to visualize alpha-synuclein aggregates in the human brain, enabling direct assessment of disease pathology.
- ABLi plans to deploy the imaging tool across multiple clinical studies to correlate biomarker changes with functional outcomes and therapeutic response.
- The collaboration reflects growing emphasis on biomarker-driven validation of disease-modifying claims in Parkinson’s drug development.
ArkBio Receives China Marketing Authorization for Azstarys in ADHD
Pulse:
- Ark Biopharmaceutical announced that China’s NMPA has approved Azstarys for the treatment of ADHD in patients aged six years and older.
- Azstarys combines immediate-release and prodrug formulations of dexmethylphenidate to provide rapid onset and sustained symptom control throughout the day.
- The approval introduces a differentiated treatment option into a Chinese ADHD market with limited pharmacological choices and significant unmet need.
- Regulatory clearance positions ArkBio to begin commercial rollout while expanding access to modern ADHD therapies in China.
IGC Pharma Raises Capital to Advance Phase 2 Alzheimer’s Agitation Program
Pulse:
- IGC Pharma announced a registered direct offering to raise capital to support continued development of IGC-AD1, its Phase 2 cannabinoid-based therapy for agitation in Alzheimer’s dementia.
- Proceeds will be used for working capital and to sustain clinical execution of the CALMA Phase 2 trial, reflecting a disciplined financing approach rather than pipeline expansion.
- IGC-AD1 targets neuropsychiatric symptoms associated with Alzheimer’s disease, an area of high unmet need that significantly impacts patient quality of life and caregiver burden.
- The financing supports incremental progress in a challenging development area where symptom-focused interventions remain clinically and commercially relevant.
Kenai Therapeutics Receives $8M CIRM Grant for Neuron Replacement Therapy in Parkinson’s
Pulse:
- Kenai Therapeutics received an $8 million grant from the California Institute for Regenerative Medicine to advance RNDP-001, an off-the-shelf neuron replacement therapy for idiopathic Parkinson’s disease.
- RNDP-001 is designed to replace lost dopaminergic neurons rather than manage symptoms, representing a regenerative approach to Parkinson’s treatment.
- The therapy is currently being evaluated in a Phase 1 clinical trial assessing safety, tolerability, and evidence of cell survival and functional integration.
- CIRM’s funding reinforces confidence in cell-based strategies aimed at restoring neural circuitry in neurodegenerative disease.
China Accepts Biologics License Application for Subcutaneous LEQEMBI in Early Alzheimer’s
Pulse:
- Eisai and Biogen announced that China’s NMPA has accepted the biologics license application for a subcutaneous formulation of LEQEMBI (lecanemab) for early Alzheimer’s disease.
- If approved, the subcutaneous autoinjector would allow patients to initiate and maintain treatment at home, reducing reliance on infusion centers and easing the healthcare system burden.
- The formulation builds on LEQEMBI’s anti-amyloid mechanism while addressing real-world delivery challenges, particularly in a large and rapidly aging patient population.
- Acceptance of the application signals regulatory openness to alternative dosing routes that may accelerate adoption and broaden access to disease-modifying Alzheimer’s therapies in China.
Bright Minds to Announce Topline Phase 2 Results for BMB-101 in Rare Epilepsy
Pulse:
- Bright Minds Biosciences announced it will report topline results from its Phase 2 trial of BMB-101 in patients with drug-resistant absence seizures and developmental and epileptic encephalopathies, with data scheduled for release via webcast.
- BMB-101 is a highly selective serotonergic agonist designed to address seizure disorders with limited treatment options, reflecting Bright Minds’ focus on precision targeting within neuropsychiatric and neurological indications.
- The Phase 2 study evaluates BMB-101 in patient populations where seizure control remains difficult despite existing therapies, positioning the readout as an important validation point for the company’s platform.
- Topline results will help determine next development steps and the broader applicability of selective serotonin receptor modulation in rare and pediatric epilepsy syndromes.
Coya Therapeutics Secures FDA IND Acceptance for COYA 302 in Frontotemporal Dementia
Pulse:
- Coya Therapeutics announced FDA acceptance of its IND application for COYA 302, an investigational biologic therapy for frontotemporal dementia.
- COYA 302 is designed to enhance regulatory T-cell function and reduce neuroinflammation, targeting a disease with no approved disease-modifying treatments.
- The IND enables initiation of controlled clinical trials in sporadic FTD, while Coya continues to explore the therapy’s relevance across multiple neurodegenerative conditions.
- Regulatory clearance marks an important step in advancing immunomodulatory strategies within the dementia landscape.
Epilepsy Foundation Launches “Give26” National Fundraising Campaign
Pulse:
- The Epilepsy Foundation of America launched Give26, a national fundraising initiative highlighting that one in 26 people in the U.S. will develop epilepsy during their lifetime.
- The campaign includes matched and tripled donations during January, with proceeds directed toward education, advocacy, research, and community support programs.
- Give26 underscores the ongoing need for sustained investment beyond drug development, particularly in patient services and stigma reduction.
- The initiative reflects the broader ecosystem required to support neurological disorders, where advocacy organizations play a critical role alongside industry and academia.
